OCA
PMVP icon

Octagon Capital Advisors’s PMV Pharmaceuticals PMVP Stock Holding History

Octagon Capital Advisors’s Portfolio PMVP Stock Details PMVP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-904,000
Closed -$5.55M – 44
2023
Q3 		$5.55M Buy
904,000
+434,000
+92% +$2.98M 0.85% 24
2023
Q2 		$2.94M Buy
+470,000
New +$2.46M 0.41% 31
2021
Q4 		– Sell
-100,141
Closed -$2.98M – 33
2021
Q3 		$2.98M Sell
100,141
-149,859
-60% -$4.78M 0.73% 26
2021
Q2 		$8.54M Hold
250,000
– – 1.77% 18
2021
Q1 		$8.22M Hold
250,000
– – 3.1% 13
2020
Q4 		$15.4M Buy
+250,000
New +$9.81M 5.33% 6

Other funds holding PMVP

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return
EC
Euclidean Capital New York $392M AUM 31.85% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Alkeon Capital Management
Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
Verition Fund Management
Verition Fund Management Greenwich, Connecticut $15.4B AUM 30.69% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return

Octagon Capital Advisors's PMVP Position: Q4 2023 in Review

Octagon Capital Advisors sold out of PMV Pharmaceuticals (PMVP) in Q4 2023, closing a stake of 904,000 shares — an estimated $5.55M sold.

Octagon Capital Advisors first reported a position in PMVP in Q4 2020 and held it in 6 quarters. The position peaked at $15.4M in Q4 2020. 98 funds tracked by Wall St. Rank hold PMVP as of Q4 2023.

  • Octagon Capital Advisors reported no remaining PMV Pharmaceuticals position as of Q4 2023 after selling out during the quarter.
  • Octagon Capital Advisors sold 904,000 PMV Pharmaceuticals shares in Q4 2023, an estimated $5.55M.
  • Octagon Capital Advisors first reported a position in PMV Pharmaceuticals in Q4 2020 and held it in 6 quarters.
  • Octagon Capital Advisors's PMV Pharmaceuticals position peaked at $15.4M in Q4 2020.
  • 98 funds tracked by Wall St. Rank held PMV Pharmaceuticals as of Q4 2023.

Based on Octagon Capital Advisors's 13F filing for Q4 2023, filed 14 Feb 2024.